The Online Investor

Slideshow Mega-Mergers: Largest Recent M&A Transactions

By The Online Investor Staff, updated Tue., Dec. 6, 9:18 AM

Slide #1. Eli Lilly and Company Akouos, Inc.

Acquirer: Eli Lilly and Company (LLY)
Acquiree: Akouos, Inc. (AKUS)
Details: Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.

Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.

Eli Lilly SEC Filing Email Alerts Service


Open the LLY Page at The Online Investor »

Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.

Eli Lilly SEC Filing Email Alerts Service


Open the AKUS Page at The Online Investor »

Company Name: 
Lilly (Eli) & Co
Stock buyback: 
LLY buyback
Website: 
www.lilly.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding LLY: 
124
Total Market Value Held by ETFs: 
$24.13B
Total Market Capitalization: 
$351.88B
% of Market Cap. Held by ETFs: 
6.86%
Company Name: 
Akouos Inc
Website: 
www.akouos.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding AKUS: 
2
Total Market Value Held by ETFs: 
$6.06M
Total Market Capitalization: 
$485.00M
% of Market Cap. Held by ETFs: 
1.25%
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Mega-Mergers Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.